A Phase 2b, Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Ranging Study Of Oral Pf-06651600 And Pf-06700841 As Induction And Chronic Therapy In Subjects With Moderate To Severe Ulcerative Colitis

Trial Profile

A Phase 2b, Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Ranging Study Of Oral Pf-06651600 And Pf-06700841 As Induction And Chronic Therapy In Subjects With Moderate To Severe Ulcerative Colitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2018

At a glance

  • Drugs PF 6651600 (Primary) ; PF 6700841 (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms Vibrato
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Jun 2018 Planned End Date changed from 28 Jan 2020 to 19 Jun 2021.
    • 05 Jun 2018 Planned primary completion date changed from 12 Jul 2019 to 6 Dec 2020.
    • 20 Mar 2017 Planned End Date changed from 1 Jan 2020 to 28 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top